title: A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.
abstract: The potential for enhancing the immunogenicity of recombinant (baculovirus-derived) influenza hemagglutinin (rHA) was investigated by comparing the immune responses elicited in mice by an intranasal (i.n.) rHA formulated with Proteosomes, with those induced by intramuscular (i.m.) or i.n. rHA alone. The Proteosome-rHA vaccine induced mucosal responses in the respiratory tract, as well as high serum IgG and hemagglutination inhibition (HAI) titers. In contrast, rHA alone given i.m. induced serum IgG without mucosal responses and was ineffective at inducing either mucosal or systemic responses when given i.n. Only mice immunized with the Proteosome-rHA vaccine were completely protected from both death and acute morbidity following live virus challenge, indicating that the i.n. Proteosome-rHA vaccine induced more complete protective immunity than the same doses of unformulated rHA given i.n. or i.m.
authors.affiliation: ID Biomedical Corporation of Quebec, 7150 Frederick Banting, Suite 200, Ville Saint-Laurent, Montreal, Que., Canada H4S 2A1. tjones@idbiomedical.com
authors.forename: Taff
authors.initials: T
authors.lastname: Jones
authors.forename: Francine
authors.initials: F
authors.lastname: Allard
authors.forename: Sonya L
authors.initials: SL
authors.lastname: Cyr
authors.forename: Steven P
authors.initials: SP
authors.lastname: Tran
authors.forename: Martin
authors.initials: M
authors.lastname: Plante
authors.forename: Joelle
authors.initials: J
authors.lastname: Gauthier
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bellerose
authors.forename: George H
authors.initials: GH
authors.lastname: Lowell
authors.forename: David S
authors.initials: DS
authors.lastname: Burt
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D016367:Baculoviridae / Q000276:immunology*; D002626:Chemistry, Pharmaceutical; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006388:Hemagglutinins / Q000276:immunology*; D018928:Immunity, Mucosal / Q000276:immunology*; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007202:Indicators and Reagents; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control; D010641:Phenotype; D013154:Spleen / Q000166:cytology / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D016207:Cytokines; D006388:Hemagglutinins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007202:Indicators and Reagents; D007252:Influenza Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic